Alpha Tau Medical enters the final stretch before its August 12 earnings with a continued divergence between relentless CFO selling and a stock that refuses to break down.
The CFO storyline has only deepened since the last note. Raphi Levy has been selling consistently since late June — transactions on June 23, 25, 30, July 1, 2, and 6 totalling roughly $1.1 million in proceeds. The share price during those sales ranged from $9.47 to $14.00, a window that now sits below or at the current close of $13.32. The 90-day net value sold across all insider activity comes to approximately $1.27 million. These are small trades relative to the company's capitalisation, and significance scores are low, but the pattern is unmistakable: the CFO has been consistently lightening exposure into every price strength. That is a signal worth noting, particularly with the stock up 36% over the past month and 8% on the week.
The borrow picture has shifted again since the last note flagged an availability snap-back to 90%. Availability has loosened further to around 79% — well off the tightest reading of 26% seen on July 16 but still tighter than the 90%-plus levels visible earlier in the month. Cost to borrow ticked down to 8.8% from a weekly high near 9.8%, though it remains meaningfully elevated for a name of this size. Short interest is essentially flat on the week at 2.6% of the free float — low in absolute terms — and the 30-day build that had been running at 30% in the prior note has moderated to 14%. The borrow market reads as manageable rather than pressured, with enough availability to accommodate new short positions without a squeeze dynamic.
Options traders are not hedging into the print. The put/call ratio is running at 0.17, almost exactly in line with its 20-day average of 0.17 and a z-score near zero — meaning there is no unusual tilt toward either protection or speculation right now. The 52-week range for the PCR is 0.0 to 6.75, so the current reading sits in deeply call-dominated territory. Combined with an ORTEX short score of 57 — stable over the past week and a half — the positioning picture is broadly neutral, neither crowded short nor defensively hedged.
The Street remains constructive but not unanimous. HC Wainwright reiterated its Buy and $15 target as recently as July 22. Barclays, which initiated in late May, bumped its Overweight target from $15 to $17 in early June. The lone holdout is Piper Sandler, which carries a Neutral and a $8 target — a meaningful gap from the $14.20 consensus mean. With the stock at $13.32, the upside to consensus is thin. The bull case centres on the Tolmar partnership for urologic cancers and upcoming pancreatic cancer pilot data. Bears point to FDA approval uncertainty and reimbursement risk for a clinical-stage company still burning cash — the EV/EBITDA multiple is deeply negative at -30, consistent with pre-profitability biotech territory.
Earnings history provides a useful frame. The last four prints produced next-day moves of +9.5%, +3.1%, +4.2%, and +6.7% — all positive on day one, with mixed five-day follow-through. The August 12 event is the next inflection point: the pancreatic cancer data readout and any update on Tolmar commercialisation momentum are the data points that will determine whether that positive-reaction pattern holds.
See the live data behind this article on ORTEX.
Open DRTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
